| Name | Title | Contact Details |
|---|---|---|
Pascal Wotling |
Chief Technical Operations Officer | Profile |
We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.
Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
Genpathway, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.